An observational study in Chronic Obstructive Pulmonary Disease, sponsored by Fu Jen Catholic University. Recruiting at 2 sites in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Fu Jen Catholic University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Pulmonary Disease, Chronic Obstructive by Fu Jen Catholic University — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Fu Jen Catholic University.
Among the 13 studies in Pulmonary Disease, Chronic Obstructive by Fu Jen Catholic University, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 13th registered.
5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →4 of the 13 studies in Pulmonary Disease, Chronic Obstructive by Fu Jen Catholic University are open now, in 1 country. Recruiting first, the newest first:
Fu Jen Catholic University · Sites in Taiwan
Ages 45–65 · Healthy volunteers
Fu Jen Catholic University · Sites in Taiwan
Ages 18+
Fu Jen Catholic University · Sites in Taiwan
Ages 20–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 180 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 35 across the 9 interventional studies, 45 across the 4 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fu Jen Catholic University is the lead sponsor of 48 studies on the registry; 22 are open to participants now.
4 of the studies in Pulmonary Disease, Chronic Obstructive by Fu Jen Catholic University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07474220Fu Jen Catholic UniversityExpression of SLC25A48 in Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT06579872Fu Jen Catholic UniversityAssociation Between Cardiopulmonary Function and Plantar Pressure in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT06717659Fu Jen Catholic UniversityProbiotics in Pulmonaty Rehabilitation for COPD | 2026-12-31 |
| NCT06168266Fu Jen Catholic UniversityEffects of Eccentric Exercise Training in Patients With COPD | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Pulmonary Disease, Chronic Obstructive by Fu Jen Catholic University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the expression level of SLC25A48, a mitochondrial choline transporter, in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease, and to analyze its correlation with inflammatory markers and choline metabolic byproducts.
Background:
Chronic obstructive pulmonary disease is the third leading cause of death worldwide, characterized by airflow limitation, alveolar damage, and chronic systemic inflammation. These features are closely associated with malnutrition, muscle loss, and oxidative stress. Mitochondrial dysfunction plays a critical role in immune dysregulation, with peripheral blood mononuclear cells widely used in studies on inflammation and metabolism. Choline, essential for one-carbon metabolism and immune function, requires specific transporters to enter mitochondria. SLC25A48, a newly identified mitochondrial choline transporter, is linked to impaired choline uptake, elevated reactive oxygen species, and metabolic imbalance. However, its role in chronic obstructive pulmonary disease remains unclear.
Study Design:
This multicenter, prospective observational study
Methods:
The expression of SLC25A48 in peripheral blood mononuclear cells will be quantified and analyzed in relation to inflammatory markers and choline metabolism indicators. All participants will undergo pulmonary function testing, nutritional and quality of life assessments, and blood biochemistry. Peripheral blood mononuclear cells will be isolated using density gradient centrifugation, followed by protein extraction and quantification via Western blot and image-based analysis.
patient of hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines
healthy controls
expression of SLC25A48
the expression level of SLC25A48 in mitochondria isolated from peripheral blood mononuclear cells
Time frame: one day
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 6 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Fu Jen Catholic University